Financing ·
CAMP4 gets Australian regulatory clearance for Phase 1/2 trial, unlocking up to $50.1M in private placement proceeds
CAMPCamp4 Therapeutics Corp
CAMP4 Therapeutics Corporation received regulatory clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder. This regulatory milestone satisfies a condition in the company's September 2025 Securities Purchase Agreement, making the company eligible to receive up to $50.1 million in gross proceeds from a second closing of a private placement in exchange for up to 32,721,172 shares of common stock or pre-funded warrants. The second closing is expected to occur on or about August 3, 2026. CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics for genetic diseases.